CD19 is a protein on B cells from the start until they mature. It’s always there, even on cancerous B cells. This makes CD19 ...

The T-cell malignancies market is driven by the rising incidence of these cancers, advancements in treatment options, and ...

Multiple players are exploring whether modalities designed to combat B cell malignancies can be repurposed against lupus, myasthenia gravis and other conditions traced to misdirected immune response.

Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biopharmaceutical ...

(MENAFN- AETOSWire) (BUSINESS WIRE ) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, today announced it will share new data across a range of B-cell malignancies ...

Discover five T cell engager companies that have emerged in recent times, as this class of therapeutics is set to take off.

Discover how next-generation "switchable" CAR-T cells could improve both the safety and efficacy of CAR-T therapies.

PHILADELPHIA, PA — Interius BioTherapeutics has taken a significant step forward with the dosing of its first participant in ...

Sana Biotechnology has become the latest cell therapy biotech to shift resources from cancer to autoimmune diseases as part of a ...

Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage allogeneic cell therapy and genetic medicines company advancing ...

Cellectis is confident about the continued progress of its ongoing clinical trials in hematological malignancies and is ...

CASGEVY approved for the treatment of patients 12 years of age and older with sickle cell disease (SCD) and transfusion-dependent beta thalassemia (TDT) in Switzerland and Canada- -45 authorized treat ...